Evaluation of p53 and Bcl-2 expression with Ki-67 proliferation index in prostatic aciner adenocarcinoma, their correlation with histopathological and clinical prognostic factors;Prostatik asiner adenokarsinomda p53 ve Bcl-2 ekspresyonlari ile Ki-67 proliferasyon indeksinin deǧerlendirilmesi, histopatolojik ve klinik prognostik faktörlerle ilişkisi

Turk Uroloji Dergisi

Volumn 29, Issue 3, 2003, Pages 250-257

  Sahan E ^a   Tetikkurt, U S ^a   Balci, C ^a   Igdem A A ^a   Gultekin S E ^a   Erdogan N ^a  

^a ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adenocarcinoma; Bcl 2; Ki 67; p53; Prostate

Indexed keywords

KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER INFILTRATION; CANCER INVASION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CAUSE OF DEATH; CELL CYCLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE; MALE; ONCOLOGICAL PARAMETERS; PREDICTION; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; REGULATORY MECHANISM; RETROSPECTIVE STUDY; SCORING SYSTEM; SEMINAL VESICLE; STATISTICAL ANALYSIS; SURVIVAL TIME; TRANSURETHRAL RESECTION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; URINARY TRACT CANCER;

EID: 0141483604     PISSN: 13005804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Isaacs W, Freije D, Isaacs S, Walsh P: Genetic predisposition to prostate cancer. Prospectives vol 6: No 3, 1996.
2. Yeşil Y: Prostat kanserinde biyopsi bulgularinin ekstraprostatik yayilimla ilişkisi. Uzmanlik tezi. TEAH Üroloji Kliniǧi. Instanbul, 2000.
3. Cotran RS, Kumar V, Robbins SL (eds): Prostate, The Male Genital Tract. Chapter 23. In Robbins Pathologic Basis of Disease (6th ed). WB Saunders Company, United States of America ss 1024-1033, 1999
4. Damjanov I, Linder J: Male Reproductive System. Chapter 67. In: Damjanov I (eds) Anderson's Pathology (10th ed). Mosby, St. Louis ss 2197-2219, 1990.
5. Foster CS, Mc Louglin S, Bashir I: Markers of the metastatic fenotip in prostate cancer. Hum Pathol 23: 381-394, 1992.
6. Gaox, Porter AT, Gripnon DJ: Diagnostic and prognostic markers for human prostate cancer. The Prostate 31: 264-281, 1997.
7. Peterson RD: Prostate and seminal vesicle. In Peterson RO (eds) Urologic Pathology (2nd ed). JB Lippincott Company, Philadelphia 603-634, 1992.
8. Rosai J: Male Reproductive System. Chapter 18. In: Rosai J (eds) Ackerman's Surgical Pathology (8th ed). Mosby, St: Louis ss 1221-1256, 1996.
9. Moul Judd W: Angiogenesis, p53, bcl-2, Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 35: 399-407, 1999.
10. Hockenbury D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334, 1990.
11. Colombel M, Olsson CA, Ng PY, Buttyan R: Hormone regulated apoptosis results from re-entry of differentiated prostate cells onto a defective cell cycle. Cancer Res 52: 4313, 1992.
12. Colombel M, Symmans F, Gil S, O'toole KM, Chopin D, Benson MM, Olsson CA, Vorsmeyer S, Battyou R: Detection of the apoptosis-suppressing onco-protein bcl-2 in hormone refractory prostate cancers. Am J Pathol 143:390-400, 1993.
13. Kallakury Bhaskar VS, Jamees F, Jeffrey SR, Fisheer Hugh AG, Figge Helen L, Pharm D and Jennings Timothy A: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 25: 92-97, 1994.
14. Murphy William M (eds): Disease of the prostate gland and seminal vesicle Chapter Male Genital Tract. In: Urological Pathology (2nd ed). WB Saunders Company USA ss 181-230, 1997.
15. Keshgegian Albert A, Elaine J and Cnaan A: Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110: 443-449, 1998.
16. Thomas DJ, Robbinson M, King P, Hasan T, Charlton R, Martin J, Carr TW and Neal DE: p53 expression and clinical outcome in prostate cancer. British Journal of Urology 72:778-781, 1993.
17. Bower John J, Sesterhenn Isabell A, Mostofi FK, Mclead David G, Shiv S and Moul Judd W: Protein expression of p53, bcl-2 and Ki-67 (MIB1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. The Journal of Urology. Oct vol 156: 1511-1516, 1996.
18. Munshi A, Byrne P, Ramesh R, Freeman SM, Marrogi AJ. p53 molecule as a prognostic marker in human malignencies. J La State Med Soc Apr 150(4):175-8, 1998.
19. Stapleton AM, Zbell P, Kaattan MW, Yang G, Wheeler TM, Scardino PT, Thompson TC: Assessment of the biologic markers p53, Ki-67 and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer Jan 82(1): 168-75, 1998.
20. Thompson SJ, Meellon KK, Charlton RG, Marsh C, Robinson M, Neal DE: p53 and Ki-67 immunreactivity in human prostate cancer and benign hyperplasia. Br J Urol Jun 69(6): 609-13, 1992.
21. Mc Loughlin J, Foster CS, Price P, Gordon W and Abel PD: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostate carcinoma. British Journal of Urology 72: 92-97, 1993.
22. Bauer John J, Sesterhenn Isabel A, Mostofi FK, Mc Leod David G, Shiv S and Moul Judd W: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic bio-markers in surgically treated clinically localized prostate cancer. The Journal of Urology Oct vol 156: 1511-1516, 1996.
23. Lu QL, Abel P, Foster CS, Lalani EN: Bcl-2 role in epithelial differentiation and oncogenesis. Hum Pathol, Feb 27(2): 102-10, 1996.